Cellectar Biosciences Enrolls First Patient in Phase 1b Trial of CLR 125 for Refractory Triple-Negative Breast Cancer

Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial evaluating CLR 125, an investigational auger-emitting radioconjugate. The study is focused on treating patients with refractory triple-negative breast cancer (TNBC), a form of breast cancer that lacks three common receptors—estrogen, progesterone, and HER2—and is often resistant to standard therapies.

The trial aims to assess the safety, tolerability, and preliminary efficacy of CLR 125 in individuals who have not responded to previous treatments for TNBC. CLR 125 is designed to deliver targeted radiation directly to cancer cells while minimizing exposure to surrounding healthy tissue. This approach utilizes auger electrons, which are known for their ability to cause localized damage at the cellular level. Cellectar’s enrollment marks a significant step forward in advancing research into potential treatment options for this aggressive type of breast cancer. Further updates on the progress of the trial are expected as additional patients are recruited and data becomes available.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 14, 2026

Author

GOAI